Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153).

Data from this large predominantly community-based study, which included patients aged ≥70 years and with an ECOG PS of 2, are consistent with registrational studies. As expected, the median OS for patients with an ECOG PS of 2 was lower than for the overall population, but comparable with historical data.